Circassia Pharma
Northbrook House
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA
United Kingdom
Website: http://www.circassia.co.uk/
57 articles about Circassia Pharma
-
Circassia Inc. Significantly Expands Reach of NIOX® FeNO Asthma Testing and Management Device With National Primary Care Distributor Agreements
4/26/2022
Circassia Inc. announced today that it has successfully engaged with major primary care national sales partners to expand the distribution of NIOX VERO®, its FeNO testing device in the United States.
-
While there is no cure for the disease, there are a number of drugs that have been approved to treat the illness. And with the growing number of cases, the drug market for COPD is expected to dramatically increase as well.
-
Circassia Pharmaceuticals launches DUAKLIR® PRESSAIR® (aclidinium/formoterol) for patients with Chronic Obstructive Pulmonary Disease (COPD)
10/21/2019
Only twice-daily LAMA /LABA in the United States with COPD exacerbation data included in its prescribing information
-
Circassia Pharmaceuticals Receives Innovative Technology Supplier of the Year Award from Vizient
6/13/2019
Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that it has been awarded the “Innovative Technology Supplier of the Year” award by Vizient, Inc., the largest member-driven health care performance improvement company in the country.
-
US Food and Drug Administration Approves DUAKLIR® PRESSAIR® (aclidinium/formoterol) for Patients with Chronic Obstructive Pulmonary Disease (COPD)
4/17/2019
Only twice-daily LAMA /LABA in the United States with COPD exacerbation data included in its prescribing information
-
COPD is a progressive disease associated with tobacco smoking, air pollution or occupational exposure. It results in difficulties in breathing and increasing episodes of breathlessness.
-
FDA Approves TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) Supplemental New Drug Application (sNDA) to include data for the Reduction of COPD Exacerbations and Hospitalizations
3/29/2019
Label Updated to Include Reduction in Exacerbations and Major Adverse Cardiovascular Event Safety Data in Cardiovascular-Risk COPD Patients
-
Circassia Announces Duaklir Successfully Met Primary Endpoints In AMPLIFY Phase III Study In Chronic Obstructive Pulmonary Disease
9/7/2017
-
Circassia Finally Throws In The Towel On Allergy Program After Trial Failures
4/18/2017
-
Circassia Surges After Scoring $300 Million Respiratory R&D Deal With AstraZeneca PLC
3/17/2017
-
Circassia Stock Crashes as Allergy Drug Flunks Crucial Phase III Study
6/20/2016
-
ERT Integrates Circassia’s FeNO Device to Assess Patient Airway Inflammation
5/18/2016
-
Circassia Announces Positive Outcome Of European Decentralised Procedure For Approval Of Its Fluticasone Propionate Equivalent Of GlaxoSmithKline’s FLIXOTIDE pMDI
11/24/2015
-
Circassia Business Update
10/27/2015
-
Circassia Release: Interim Results For The Six Months Ended 30 June 2015
7/28/2015
-
Circassia’s Extended Offer Period For Aerocrine Has Increased Acceptances To 97.2 Percent
6/30/2015
-
Circassia Release: Completion Of Acquisition Of Prosonix
6/15/2015
-
Circassia Declares The Offer For Aerocrine Unconditional And Extends The Acceptance Period
6/15/2015
-
Circassia To Present At EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015
6/4/2015
-
Circassia Drops $377 Million for Two Asthma Firms, Aerocrine and Prosonix
5/15/2015